The Critical Path Institute Adopts the Rosetta Biosoftware's Rosetta Resolver(R) System for the Predictive Safety Testing Consortium

SEATTLE & TUCSON, Ariz.--(BUSINESS WIRE)--Rosetta Biosoftware announced today that The Critical Path Institute (C-Path) adopted the Rosetta Resolver® system for C-Path’s Predictive Safety Testing Consortium. The Consortium brings together major pharmaceutical companies to work in collaboration with C-Path and the U.S. Food and Drug Administration (FDA). The Consortium's objective is to enable the exchange of knowledge and resources to improve drug safety. The Resolver system will be used by the Consortium as a central data management and analysis system as it develops standards for the qualification of tests to evaluate the safety and toxicity of drugs submitted for FDA approval.